Susquehanna International Group
MCRB icon

Susquehanna International Group’s Seres Therapeutics MCRB Stock Holding History

Susquehanna International Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$576K Sell
64,900
-19,300
-23% -$226K ﹤0.01% 9302
2025
Q4 		$1.25M Buy
84,200
+7,600
+10% +$133K ﹤0.01% 6653
2025
Q3 		$1.47M Buy
76,600
+59,300
+343% +$946K ﹤0.01% 6447
2025
Q2 		$192K Buy
17,300
+16,055
+1,290% +$141K ﹤0.01% 11255
2025
Q1 		$17.4K Sell
1,245
-5,265
-81% -$82.4K ﹤0.01% 12144
2024
Q4 		$108K Sell
6,510
-9,115
-58% -$148K ﹤0.01% 11282
2024
Q3 		$297K Sell
15,625
-1,115
-7% -$22.6K ﹤0.01% 9624
2024
Q2 		$241K Buy
16,740
+2,690
+19% +$44.9K ﹤0.01% 9944
2024
Q1 		$216K Buy
14,050
+11,925
+561% +$257K ﹤0.01% 10446
2023
Q4 		$59.5K Buy
2,125
+630
+42% +$16.5K ﹤0.01% 11646
2023
Q3 		$71.2K Sell
1,495
-9,715
-87% -$741K ﹤0.01% 11129
2023
Q2 		$1.07M Buy
11,210
+8,995
+406% +$979K ﹤0.01% 6516
2023
Q1 		$251K Buy
2,215
+515
+30% +$55.7K ﹤0.01% 10110
2022
Q4 		$190K Sell
1,700
-4,070
-71% -$546K ﹤0.01% 10201
2022
Q3 		$741K Sell
5,770
-5
-0.1% -$512 ﹤0.01% 7417
2022
Q2 		$396K Buy
5,775
+3,210
+125% +$277K ﹤0.01% 8832
2022
Q1 		$365K Sell
2,565
-3,105
-55% -$478K ﹤0.01% 9767
2021
Q4 		$945K Buy
5,670
+2,310
+69% +$367K ﹤0.01% 7456
2021
Q3 		$468K Sell
3,360
-1,195
-26% -$234K ﹤0.01% 9568
2021
Q2 		$2.17M Buy
4,555
+415
+10% +$175K ﹤0.01% 5726
2021
Q1 		$1.71M Sell
4,140
-3,430
-45% -$1.58M ﹤0.01% 6307
2020
Q4 		$3.71M Buy
7,570
+4,615
+156% +$2.7M ﹤0.01% 3940
2020
Q3 		$1.67M Sell
2,955
-4,580
-61% -$1.52M ﹤0.01% 4957
2020
Q2 		$717K Buy
+7,535
New +$661K ﹤0.01% 6605
2020
Q1 		– Sell
-970
Closed -$67K – 10626
2019
Q4 		$67K Buy
970
+215
+28% +$15.9K ﹤0.01% 9268
2019
Q3 		$61K Sell
755
-1,490
-66% -$98.5K ﹤0.01% 9732
2019
Q2 		$145K Buy
2,245
+570
+34% +$54.1K ﹤0.01% 9397
2019
Q1 		$230K Buy
1,675
+1,065
+175% +$130K ﹤0.01% 7658
2018
Q4 		$55K Hold
610
– – ﹤0.01% 8448
2018
Q3 		$93K Sell
610
-200
-25% -$32.4K ﹤0.01% 8631
2018
Q2 		$139K Sell
810
-40
-5% -$6.54K ﹤0.01% 8894
2018
Q1 		$125K Sell
850
-2,480
-74% -$476K ﹤0.01% 8612
2017
Q4 		$675K Sell
3,330
-9,585
-74% -$1.97M ﹤0.01% 6027
2017
Q3 		$4.14M Buy
12,915
+11,205
+655% +$3.06M ﹤0.01% 2761
2017
Q2 		$386K Buy
1,710
+485
+40% +$99.6K ﹤0.01% 7122
2017
Q1 		$276K Sell
1,225
-1,435
-54% -$291K ﹤0.01% 7472
2016
Q4 		$527K Sell
2,660
-920
-26% -$201K ﹤0.01% 6861
2016
Q3 		$880K Buy
3,580
+1,995
+126% +$700K ﹤0.01% 5033
2016
Q2 		$921K Buy
1,585
+630
+66% +$370K ﹤0.01% 5031
2016
Q1 		$507K Sell
955
-265
-22% -$138K ﹤0.01% 6375
2015
Q4 		$856K Buy
+1,220
New +$802K ﹤0.01% 5733

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Susquehanna International Group's MCRB Position: Q1 2026 in Review

Susquehanna International Group reduced its Seres Therapeutics (MCRB) stake by 41% in Q1 2026, selling an estimated $874K and leaving 105,339 shares worth $934K. The position accounts for ﹤0.01% of the portfolio, ranked #8048.

Susquehanna International Group first reported a position in MCRB in Q3 2015 and has held it in 31 quarters since. The position peaked at $5.29M in Q4 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • Susquehanna International Group held 105,339 shares of Seres Therapeutics worth $934K as of Q1 2026.
  • Susquehanna International Group sold 74,590 Seres Therapeutics shares in Q1 2026, an estimated $874K.
  • Seres Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8048 holding.
  • Susquehanna International Group first reported a position in Seres Therapeutics in Q3 2015 and has held it in 31 quarters since.
  • Susquehanna International Group's Seres Therapeutics position peaked at $5.29M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.